No. studies and patients included for each outcome of interest. Major outcomes are in bold face.
| Outcome | Studies | Patients |
|---|---|---|
| Endstage renal disease | 17 | 1388 |
| Renal response, including stable kidney function | 12 | 1290 |
| Renal relapse | 14 | 627 |
| Deterioration of kidney function | 13 | 993 |
| Malignancy | 14 | 1128 |
| Herpes zoster | 17 | 1423 |
| Gastrointestinal side effects | 13 | 1526 |
| Alopecia | 5 | 751 |
| Nausea | 5 | 717 |
| Diabetes/hyperglycemia | 6 | 670 |
| Avascular necrosis/osteonecrosis | 2 | 129 |
| Mortality | 30 | 6565 |
| Mycobacterial infections | 2 | 554 |
| Amenorrhea | 2 | 180 |
| Urinary bladder toxicity | 2 | 79 |
| Cytopenia | 4 | 584 |